Golden
Merlin BioMed

Merlin BioMed

Merlin BioMed was a New York City based investment advisor which invested in biotechnology, pharmaceuticals, medical devices and healthcare sectors.

Merlin BioMed was a New York City based investment advisor. Founded in 1998 by Dr. Stuart T. Weisbrod, Merlin BioMed encompasses several hedge funds. Managed by healthcare professionals, they invest in biotechnology, pharmaceuticals, medical devices and healthcare sectors.



Investment

Merlin BioMed has made investments in CymaBay Therapeutics, Gemin X Pharmaceuticals, Calypso Medical, EUSA Pharma, RenaMed Biologics, GeneLabs Technologies, FibroGen, ARYx Therapeutics, Salient Surgical Technologies, ARIAD Pharmaceuticals, Ventaira Pharmaceuticals, Confluent Surgical, De Novo Pharmaceuticals, Skila and Health Hero Network.



They exited their investments in FibroGen, CymaBay Therapeutics, Salient Surgical Technologies, Gemin X Pharmaceuticals, ARYx Therapeutics, Calypso Medical, EUSA Pharma, ARIAD Pharmaceuticals, Genelabs Technologies, Confluent Surgical and Ventaira Pharmaceuticals.

Timeline

Funded Companies

2 Results
Company
Company
Website
Website
Industry
Industry
Location
Location

People

Name
Role
LinkedIn







Further reading

Title
Author
Link
Type
Date









Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References